Skip to main content

Advertisement

Table 3 Characteristicsof “HBVreactivated” patients. 10 patients over 498 had HBV reactivation

From: Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma

Patient no. Age (years) Sex Stage of lymphoma Indolent aggressive (0-1) Baseline At diagnosis of HBV reactivation Time of diagnosis of HBV Reactivation Time to HBV recovery Nuc therapy duration Follow up HBsAg status Outcome
HBs-Ag HBV- DNA (UI/μL) ALT (U/L) Rituximab (yes/no) Therapy HBV- DNA (UI/μL) Peak ALT (XN.V.) Weeks after NHL therapy Weeks after NUC start Weeks Pos/neg  
1 50 F IV 1 - 0 23 y CHOP-R 350.000 4,5x 40 4 28 Neg Alive (NHL remission)
2 73 M IV 0 - 0 26 n VNCOP-B 450.000 10x 24 8 Ongoing Neg Alive (NHL relapse)
3 64 F I 1 - 0 34 y Fludara-R 650.000 12x 12 4 22 Neg Alive (NHL remission)
4 62 M   1 - 0 22 y CHOP-R 130.000 4x 44 3 Ongoing Pos Alive (NHL relapse)
5 50 F II 1 - 0 28 y CHOP-R 910.000 20x 20 8 44 Neg Alive (NHL remission)
6 71 M IV 0 - 0 19 n CHOP 160.000 11x 24 6 48 Neg NHL related death
7 66 M   0 - 0 36 n VNCOP-B 170.000 3,7x 20   Ongoing Pos Alive
8 70 M IV 0 - 0 31 y Fludara Nova -R 160.000 5,4x 72   Ongoing Pos Alive
9 52 F I 0 - 0 29 n CHOP 550.000 6,1x 14 7 46 Neg Alive
10 60 M IV 0 - 0 34 n CEOP, Gem, VNCOP-B 340.000 6x    Until death Pos NHL related death
  1. Of this group, everyone had HBcAb positive, HBsAg, HBsAb and HBVDNA negative status prior to start NHL therapy. Five patients were treated with Rituximab-containing protocols and five without. The mean time to HBV reactivation was 26,67 (±12,21) weeks. The mean time to HBV recovery (HBVDNA negativization and normal ALT) was 5,71 (±2,06) weeks. Five patients had HBsAg negativization after a mean time of NUC therapy of 37,80 (±11,78) weeks and stopped NUC therapy. Five patients were already in NUC therapy at the end of follow-up, due to HBV infection persistence (HBsAg positivity) and/or NHL relapse. Patient 7 to 10 have missing data, because of the retrospective nature of this study.